ProfileGDS5678 / 1433544_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 74% 75% 74% 72% 70% 74% 72% 73% 72% 73% 72% 71% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6201372
GSM967853U87-EV human glioblastoma xenograft - Control 24.9138274
GSM967854U87-EV human glioblastoma xenograft - Control 35.0088675
GSM967855U87-EV human glioblastoma xenograft - Control 44.9888474
GSM967856U87-EV human glioblastoma xenograft - Control 54.5326472
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3491170
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8042474
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5629572
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7353573
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6278372
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6797973
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6009872
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4815471
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5268572